Immunogenicity and safety of single‐dose, 13‐valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients

Hung, Te-Yu; Kotecha, Rishi S.; Blyth, Christopher C; Steed, Sarah K.; Thornton, Ruth B.; Ryan, Anne L; Cole, Catherine; Richmond, Peter

doi:10.1002/cncr.30764

Cited by 26 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T cells provide the signals required for the generation of B-cell memory (17,18). Conjugate vaccines have the potential to elicit a memory response on subsequent natural exposure to vaccine-type strains and PCV have been shown to be immunogenic in immunocompromised hosts (19)(20)(21)(22)(23) In the United Kingdom (UK), since the introduction of 7-valent PCV in 2006 and 13-valent PCV in 2010, the overall incidence of IPD has reduced by more than 50% (24).…”

Section: Title: Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine In Children With Acute Lymphoblastic Leukaemia: Protective Immmentioning

confidence: 99%

Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment

Bate

Borrow

Chisholm

et al. 2019

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Children with acute lymphoblastic leukemia (ALL) are at increased risk of developing invasive pneumococcal disease. This study describes the immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) during and after chemotherapy. Methods Children with ALL were allocated to study groups and received a single dose of PCV13: group 1, maintenance chemotherapy; group 2, end of chemotherapy; group 3, 6 months after chemotherapy. A protective vaccine response was defined as at least 10 of 12 serotypes (or >83% of serotypes with data) achieving postvaccination serotype-specific immunoglobulin G ≥0.35 µg/mL and ≥4-fold rise, compared to prevaccination at 1 and 12 months. Results One hundred eighteen children were recruited. Only 12.8% (5/39; 95% confidence interval [CI], 4.3%–27.4%) of patients vaccinated during maintenance (group 1) achieved a protective response at 1 month postvaccination and none had a protective response at 12 months. For group 2 patients, 59.5% (22/37; 95% CI, 42.1%–75.3%) achieved a response at 1 month and 37.9% (11/29; 95% CI, 20.7%–57.7%) maintained immunity at 12 months. For group 3 patients, 56.8% (21/37; 95% CI, 39.5%–72.9%) achieved a protective response at 1 month and 43.3% (13/30; 95% CI, 25.5%–62.6%) maintained immunity at 12 months. Conclusions This study demonstrated that the earliest time point at which protective immunity can be achieved in children with ALL is on completion of chemotherapy. This is earlier than current recommendations and may improve protection during a period when children are most susceptible to infection. Clinical Trials Registration EudraCT 2009-011587-11.

show abstract

Section: Title: Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine In Children With Acute Lymphoblastic Leukaemia: Protective Immmentioning

confidence: 99%

Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment

Bate

Borrow

Chisholm

et al. 2019

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…The immunogenicity of pneumococcal vaccines in cancer patients was shown in previous studies performed with PPS-V23, which demonstrated that adequate immune responses could be induced in patients undergoing chemotherapy [2,3]. As for PCV13, a recent study reported its safety and immunogenicity in children who completed cancer treatment [4]. However, data on PCV13 in adult cancer patients are lacking.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial

et al. 2020

View full text Add to dashboard Cite

Pneumococcal vaccination (13-valent pneumococcal conjugate vaccine [PCV13]) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies. Materials and MethodsWe conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating 2 weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumoniae using a multiplexed opsonophagocytic killing assay. ResultsOf the 92 patients who underwent randomization, 43 patients in arm A (vaccination 2 weeks before chemotherapy) and 44 patients in arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > 4-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments. ConclusionThe overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.

show abstract

“…Ab Geburt bis zum Alter von 2 Jahren sollten Kinder gemäß der altersentsprechenden STIKO-Impfempfehlung eine erneute Grundimmunisierung mit einem 13-valenten konjugierten Pneumokokkenimpfstoff (PCV13) erhalten [327]. Kinder ab dem Alter von 2 Jahren und Jugendliche benötigen nur eine PCV13-Impfstoffdosis, da für diese Altersgruppe bereits ein gutes Ansprechen auf eine Dosis des Konjugatimpfstoffs dokumentiert werden konnte [67,138] [13,216,282].…”

Section: Nach Antineoplastischer Therapieunclassified

Impfen bei Immundefizienz

Laws

Baumann

Bogdan

et al. 2020

Bundesgesundheitsbl

View full text Add to dashboard Cite

Immunogenicity and safety of single‐dose, 13‐valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients

Cited by 26 publications

References 21 publications

Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment

Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment

Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial

Impfen bei Immundefizienz

Contact Info

Product

Resources

About